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Abstract: 
 
Objectives: In the United States, 25% of people with type 2 diabetes are undiagnosed. 
Conventional screening models use limited demographic information to assess risk. We 
evaluated whether electronic health record (EHR) phenotyping could improve diabetes screening, 
even when records are incomplete and data are not recorded systematically across patients and 
practice locations.  
Methods: In this cross-sectional, retrospective study, data from 9,948 US patients between 2009 
and 2012 were used to develop a pre-screening tool to predict current type 2 diabetes, using 
multivariate logistic regression. We compared (1) a full EHR model containing prescribed 
medications, diagnoses, and traditional predictive information, (2) a restricted EHR model where 
medication information was removed, and (3) a conventional model containing only traditional 
predictive information (BMI, age, gender, hypertensive and smoking status). We additionally 
used a random-forests classification model to judge whether including additional EHR 
information could increase the ability to detect patients with Type 2 diabetes on new patient 
samples.  
Results: Using a patient's full or restricted EHR to detect diabetes was superior to using basic 
covariates alone (p<0.001). The random forests model replicated on out-of-bag data. Migraines 
and cardiac dysrhythmias were negatively associated with type 2 diabetes, while acute bronchitis 
and herpes zoster were positively associated, among other factors.  
Conclusions: EHR phenotyping resulted in markedly superior detection of type 2 diabetes in a 
general US population, could increase the efficiency and accuracy of disease screening, and are 
capable of picking up signals in real-world records. 
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Introduction 
 
Although roughly 25% of those with type 2 diabetes are undiagnosed in the United States, 
population-wide screening for diabetes currently is not cost-effective because of the additional 
time and laboratory testing required1-3. Intervention studies have shown that diabetes can be 
prevented in high-risk individuals3-5, while weight loss and lifestyle changes can revert the 
recently diagnosed patients (<4 years) to pre-diabetes status6. This makes population-wide 
screening not just an issue of prevention, but also one of treatment.  
 
The total estimated cost of diagnosed diabetes in 2012 reached a staggering $245 billion, a 41% 
increase since 2007. People with diagnosed diabetes, on average, have medical expenditures 
approximately 2.3 times higher than people who do not have diabetes7.  Given that expenditures 
for patients with diabetes account for 20% of healthcare spending annually, 7 and that new 
legislation bars insurers from dropping coverage of ill patients, characterizing diabetes risk 
using electronic health records (EHR) allows this financial liability to be both appreciated and 
mitigated by those bearing the financial burden of the disease. 
 
Diabetes screening risk scores combine both patient demographic information and laboratory 
testing to predict future likelihood of developing diabetes. Risk scores are derived from 
demographic information such as age, gender, comorbid hypertension, ethnicity, and body mass 
index (BMI). Laboratory tests include fasting plasma glucose concentration, oral glucose 
tolerance test or hemoglobin A1c (compared more thoroughly in 8). These tests often require 
fasting, routine blood draws, and monitoring, which can place undue burden on the patient, 
staff, and treating physician. This makes population-wide screening expensive and impractical, 
particularly in resource limited health-care settings which are the most likely to service at-risk 
patients2, 3. Laboratory tests cannot, and should not, be performed on every individual after 
every health care encounter.  
 
Diabetes screening is recommended by the U.S. Preventive Services Task Force only for 
asymptomatic adults with treated or untreated blood pressure over 135/80 mm Hg, even though 
hypertension is only one of many known risk factors for diabetes9. In this sample, 27.5% of 
patients with type 2 diabetes did not have a hypertension diagnosis; this criterion would result 
in lab tests for 1 in 3 healthy patients, while failing to identify roughly 1 in 4 patients with type 2 
diabetes. These data suggest that more sophisticated screening methods are needed, consistent 
with the Wilson and Jungner criteria10, 11. 
 
Many current diabetes risk models are not generalizable to the disproportionate number of 
ethnic/racial minorities with Type 2 diabetes in the U.S. 12. For example, the FINDRISC score 
was developed on Finnish patients13. Although it was found to be the best risk assessment tool in 
Caucasian patients8, it was suboptimal for use on Arab and Filipino populations14, 15. Therefore, 
wide-scale screening methods that assume a “one-size-fits all” approach is simply not feasible 
among heterogeneous populations. Considering that African Americans, Hispanic/Latino 
Americans, American Indians, Asian Americans, and Pacific Islander Americans are at 
particularly high risk for type 2 diabetes1, it is important to understand the unique risk factors 
that continue to drive this growing health disparity among these groups, and to assess risk 
accurately in the subpopulations most likely to have the disease. 
 
Electronic health care records are used by more than half of the nation's health care providers, 
and more than 80% of hospitals have implemented electronic records since the 2009 stimulus 
bill16. EHRs are also of interest among research investigators, as this provides a rich data 
resource that can improve research efficiency, as advocated by the NIH’s Health Care Systems 
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Collaboratory (https://www.nihcollaboratory.org/) program which engages healthcare systems 
to improve medical research17.  EHR-based phenotypes can profile individuals who may benefit 
from interventions18. In a similar fashion, an evaluation guided by EHRs may improve the 
treatment and prognosis for patients with type 2 diabetes19. For instance, usage of an EHR was 
associated with a decreased rate of emergency department visits in individuals with diabetes20, 
21, and EHR data have been used to compute the prospective risk of developing dementia in 
individuals with diabetes22. While EHRs have demonstrated potential for detecting and 
monitoring diabetes23-26, previous studies have used only a subset of all information available in 
the medical record, and typically have assessed risk only on patients for whom there were 
specific laboratory results available (e.g., fasting plasma glucose).  In order for EHR 
phenotyping to be used in practice, it must improve accuracy even when using “typical” quality 
records, containing large amounts of missing data and unsystematic recordings across practice 
locations, consistent with at-risk patients receiving inconsistent medical attention27.  
Current risk scores pose an economic and logistical challenge for population-wide screening, 
and are less sensitive to detecting diabetes in non-white populations who are more likely to have 
diabetes16,17.  More generally, automatically predicting chronic disease using electronic health 
records has numerous applications outside of clinical practice, and would open the risk-
assessment doorway to those who ultimately bear the financial burden incurred by the disease: 
the insurers.   A better estimate of risk on the part of insurers could encourage targeted patient-
education and incentive programs to reduce financial liability.    
 
EHR models extend screening, conventionally framed between the doctor and the patient, to the 
payer and the patient.  Data mining methods are powerful, but wild-type electronic records 
frequently are messy18; these tools should be validated against real-world data if realistic results 
are desired. We examine whether augmenting risk scores using EHR-derived phenotypes would 
increase sensitivity in the general population for detecting patients who should be screened 
further using laboratory testing, even when records are incomplete, and are not recorded 
systematically across health professionals and/or practice locations. When implemented on a 
population, this step-wise screening process would decrease the public health cost of more 
expensive testing, while simultaneously identifying previously overlooked at-risk patients.    
 
Subjects 
 
The study population included 9,948 patients, 18.1% diagnosed with type 2 diabetes, within the 
EHRs provided by the web-based company, Practice Fusion. Practice Fusion provides an EMR 
service which is free to health care providers.  These records were collected between 2009 and 
2012 in a retrospective study, from 1,137 unique sites spanning all 50 United States, detailed 
further in Table 1. This dataset is public and de-identified. We intentionally use an unselected 
patient population who had a wide variety of laboratory tests, prescribed medications, and 
diagnoses across 1,137 different practice locations. In contrast to a controlled research 
environment28, this EHR data approximates the diverse US clinical environment, including the 
presence of unsystematic and incomplete information reflective of at-risk patients receiving 
inconsistent medical care. 
 
Exact visit dates were removed as patient-identifying information.  A patient was labeled as 
either healthy, or having “Type 1" or “Type 2" diabetes according to at least one corresponding 
diagnosis within ICD-9 250.X category (no patients had mixed diagnoses). No ethnicity 
information was provided in this sample.  There were approximately 131,000 patient unique 
transcript entries (containing height, weight, BMI, BP, Respiratory Rate, and Heart Rate) for the 
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9,948 patients across an approximately 4 year time period, leading to roughly 2-3 
visits/year/patient, on average. 
 
Table 1: Demographic Information 
 
 
 
This dataset was rich in the breadth of information it contained: lab results; medication dosage, 
and history; basic patient demographic information (age, gender, state); smoking status; 
transcripts (BMI, systolic/diastolic blood pressure (BP), height, weight); allergies; and 
diagnosed conditions for each visit as ICD-9 codes. We identified and condensed redundant 
features manually (e.g. Warfarin and Coumadin). When BMI values were over 70, or below 10, 
we re-coded height and weight as not available (“-NA-”).  Moreover, the “Healthy Controls” in 
this sample, on average, had more prescribed medications and higher smoking rates than 
patients with Type 1 or Type 2 Diabetes.  This natural sample provided a more realistic control 
group to identify which factors in the EHR were predictive of a Type 2 diabetes diagnosis. 
 
Missing data were common in this sample: less than 1% of the patients had a recorded family 
history of diabetes (ICD9 V18.0), despite a prevalence of 11.8% in the US population. This posed 
a “worst case" scenario for prediction: given missing, unsystematic and incomplete information 
from a patient’s medical history, could residual information still augment current diabetes risk 
scores in a way that improves the accuracy and efficiency of type 2 diabetes screening in the 
general population?   
 
Materials and Methods 
 
We assessed whether Type 2 diabetes risk scores could be improved with EHR phenotypes, 
created using the additional medical and diagnostic information contained in the EHR. Because 
the visit dates were removed to protect patient privacy, longitudinal data were not available.  It 
is therefore unknown whether patients developed diabetes during their time of service, or 
whether it preceded their entry into this study.  It is similarly unknown whether patients 
identified as “healthy” had undiagnosed diabetes.  Similarly, the ordering of medications, non-
diabetes diagnoses, and the diabetes diagnosis are similarly unknown.  Using real-world clinical 
data, these models then assess the current likelihood of a patient having a current diagnosis of 
Type 2 Diabetes, rather than the future likelihood of developing diabetes. The value of including 
EHR information was computed by comparing models using a chi-square test.  
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We predicted current Type 2 diabetes status using a multivariate logistic regression in R29 
comparing three separate models: (1) Conventional Model mimicking conventional risk scores; 
(2) a full “EHR Model” based upon the EHR phenotype, containing conventional information 
and both diagnostic and prescription information; (3) “EHR DX” model which contained 
conventional information and diagnostic information. Within this model, prescription 
information was removed because a diabetes diagnosis would likely physician prescribing habits.  
Models are described in more detail below. 
 
The first model (Conventional model) mimics conventional risk scores by including only the 
limited subset of covariates (smoking status, gender, age, BMI, and hypertensive status) that 
have been used in current diabetes risk models 8, 21, and included all interaction effects. This was 
used as a reference standard in lieu of established risk scores because it ensures that difference 
between the two models is attributable to the structure and covariates, instead of the underlying 
study populations. We compared these models in a hierarchical regression with a chi-square 
test, and computed Receiver Operating Characteristic (ROC) curves by measuring the Area 
Under the Curve (AUC) within the R package ROCR 30. 
 
The second “EHR Model" used 298 features: 150 most common diagnoses, 150 most commonly 
prescribed medications (before condensing name-brand and generic), transcript information 
(Table 2), and other specialized features summarized in Table 2. Hypertensive status, 
hyperlipidemia, and metabolic diagnosis all were assessed separately. In order to reduce bias we 
removed as predictors established treatments and complications of diabetes mellitus: primary 
and secondary diabetes-related diagnoses (ICD-9 250.X, 249.X), foot ulcers (ICD-9 707.X), 
diabetic retinopathy (ICD-9 362.01), polyneuropathy in diabetes (ICD-9 357.2), diabetic cataract 
(ICD-9 366.41), and diabetes mellitus complicating pregnancy, childbirth or the puerperium 
(ICD-9 648.0X). Medications used to treat diabetes, such as metformin (GlucophageTM), were 
excluded from the model.   
 
For the EHR Model, we created an “additional risk factor” variable tallying common 
comorbidities of diabetes, including conditions that have been shown to be more common in 
diabetes, but may be caused by factors other than diabetes. These included: candidiasis of skin 
and nails, malignant neoplasm of pancreas, other disorders of pancreatic internal secretion, 
polycystic ovaries, disorders of lipoid metabolism, overweight, obesity, and other 
hyperalimentation, trigeminal nerve disorders, hypertensive heart disease, acute myocardial 
infarction, other acute and subacute forms of ischemic heart disease, old myocardial infarction, 
angina pectoris, other forms of chronic ischemic heart disease, atherosclerosis, gingival and 
periodontal diseases, disorders of menstruation and other abnormal bleeding from female 
genital tract, unspecified local infection of skin and subcutaneous tissue, acquired acanthosis 
nigricans and tachypnea. 
 
The third “EHR DX Model” used all features as in the EHR model, yet excluded all the 
medications.  This was based on the assumption that a clinician’s prescribing behavior would 
likely be influenced by a patient’s diabetes status.  Given that this sample is not longitudinal, 
excluding medication information reduces the bias inherent in all observational studies. 
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Table 2: Summary of Variables Used to Predict Diabetes 
 
 
 
 
Within the EHR model, the multivariate logistic regression implies necessarily that the 
covariates of interest and the resulting p-values are statistically dependent, making traditional 
multiple hypotheses correction methods unnecessary (e.g. Bonferroni correction). We make our 
interpretation more conservative by adjusting for the false discovery rate (FDR) using the 
graphically sharpened method, setting the maximum proportion of false discoveries at .0531, 32 as 
implemented by Pike.33 The FDR is computed over all 298 estimated p-values. We indicate 
which variables had q-values (adjusted p-values) in the FDR significance range using an asterisk 
within the regression tables, along with odds-ratio 95%-confidence intervals which take into 
account the prevalence of the risk factors being considered. 
 
Finally, we assessed the validity of these three models with a hold-out dataset using a random 
forests prediction model, to assess the sensitivity of these models to overfitting 34.  In the 
random forests model, decision trees are constructed by resampling with replacement from the 
data and the predictors.  Prediction of cases, using individual decision trees which did not 
sample that observation, provides an unbiased estimate of the testing accuracy. We run the 
random forest model using the data from the EHR model, the EHR DX model, and the 
conventional model. Machine learning methods such as random forests are undeniably more 
powerful in their prediction, and the testing accuracy they provide is an unbiased estimate of the 
predictive power on new observations.  Here, we create random forests models using a 
regression, to create similar ROC curves as the logistic models. 
 
Results 
 
The Full EHR model had sensitivity: 80.6% (78.6%-82.4%), specificity: 74.0% (72.9%-74.9%), 
and overall accuracy: 75.2% (77.3%-79.0%). When excluding medications in the EHR model, the 
overall accuracy dropped only slightly to 73.2% (72.3%-74.1%).  The DX EHR model had 
sensitivity: 79.2% (77.2%-81.0%), specificity: 71.9% (70.9%-72.8%).  The conventional model 
had sensitivity: 78.1% (76.1%-80.0%), specificity: 60.2% (59.1%-61.3%), and overall accuracy: 
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63.4% (62.4%-64.4%). All ranges correspond to 95% confidence intervals, using a decision 
threshold corresponding to the disease prevalence in the population (18.1%). All ranges reflect 
95% confidence intervals. 
 
The Full EHR model had a positive predictive value of 40.7% (39.0%-42.3%), and a negative 
predictive value of 94.5% (93.9%-95.1%). The DX EHR model had a positive predictive value of 
38.4% (36.9% - 40.0%) and a negative predictive value of 94.0% (93.3%-94.5%).  The 
conventional model had a positive predictive value of 30.3% (28.9%-31.7%) and a negative 
predictive value of 92.5% (91.8%-93.3%).  
 
The Full EHR model and the DX EHR Models both predicted better than the conventional 
models (chi-square test, p<0.001).  For the Full EHR Model, the AUC was 84.9%; for the DX 
EHR Model, the AUC was 83.2%; for the Conventional model, the AUC was 75.0%.  The 
sensitivity of the EHR models was uniformly superior for all thresholds, as shown in Figure 1. 
Factors associated significantly with a Type 2 diabetes diagnosis for the EHR model are 
presented in Table 3, with the full EHR model containing 298 coefficients and significance levels 
supplied in the Supplemental Table along with the Conventional Model.  
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Table 3: Statistically Significant Covariates to determine Type 2 Diabetes Status 
using EHR phenotypes: variables on the top half of the table decrease the 
likelihood of type 2 diabetes, while variables on the bottom half increase the 
likelihood of type 2 diabetes. Significance indicates * for P < 0.05, ** for P < 0.01, 
and *** for P < 0.001.  Q-significance indicates p-values after adjusting for the 
false-discovery rate, which controls for the total rate of falsely rejected null 
hypotheses. 
 
In the conventional model the variables age, hypertensive status, and the interaction of age with 
hypertension, all were significant predictors of type 2 diabetes. The interaction between age and 
hypertensive status indicated that younger hypertensive patients had a greater chance of type 2 
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diabetes than elderly hypertensive patients. The 298 coefficients for both the full EHR model, 
the EHR DX Model, and the conventional model are provided within the Supplementary Data 
Table 1, Table 2, and Table 3.  
 
Within the hold-out data (using the random forests probabilistic models), the EHR models had 
stronger sensitivity than the Conventional model for all thresholds, as shown in Table 4 and 
Figure 2.  The AUC for the full EHR model, the EHR DX model, and the Conventional model 
were (81.3%, 79.6%, 74.8%).  The overall accuracies were dependent on thresholds chosen, but 
for all thresholds, the ROC curve for the EHR models exceeded the sensitivity of the 
conventional model as shown in Supplementary Figure 2. Additionally, the random forest 
accuracies on the hold-out data were actually greater than the within-sample accuracy using the 
logistic regression model, demonstrating that machine-learning models have much stronger 
ability to predict chronic disease than the traditional parametric models.  The overall accuracy of 
the algorithm is somewhat less important than the sensitivity and the positive predictive value.  
Algorithms which sought only to maximize total accuracy (removing weights and thresholds) 
had higher overall accuracy (84%) but markedly inferior sensitivity, implying that they would 
rarely classify an individual as having diabetes.  
 
Table 4: Models containing both diagnostic and medication information 
performed better than the Conventional models.  While the overall accuracies 
depended on the choice of thresholding, for all thresholds the sensitivity of the 
EHR models exceeded that of conventional models. 
 
 
 
Discussion 
 
The EHR phenotype models outperformed the basic screening model for detecting individuals 
at-risk for diabetes.  While many of the risk factors identified in the full EHR model have been 
identified previously, they have not been evaluated within the context of all other clinical factors. 
Our model is not prognostic; the factors we have found associated with type 2 diabetes might be 
complications or comorbidities of the disease, rather than its cause. However, given the finding 
that type 2 diabetes was diagnosed most frequently after a patient exhibited at least one 
complication, and that 25% of patients are undiagnosed35, this situation may reflect clinical 
practice. We specifically excluded known complications of diabetes to reduce this bias, but the 
complications and causes of diabetes often can be intertwined (e.g. cardiovascular disease).  
Additionally, we demonstrated that the EHR had strong predictive power when excluding all 
physician-prescribed medications, suggesting that the diagnoses contain nearly the same 
information as the medications prescribed to treat them.   
 
Each of the discussed factors is associated with diabetes and could be used as clinical markers of 
increased risk, but should not be considered cause or consequence of the disease. For example, 
specific clinic locations were associated with an increased likelihood of current type 2 diabetes. 
This reflects different baseline prevalence of type 2 diabetes within different communities36. Due 
to the structure of our multivariate logistic regression model, each discussed factor was 
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significant, controlling for and separate from all other measured factors, while adjusting for the 
false discovery rate. 
 
We discuss first the factors that increased the likelihood of type 2 diabetes mellitus. We do not 
interpret the relative magnitude of each factor, only its sign. Hypercholesterolemia and 
hypertension are the two other pillars of metabolic syndrome37; therefore we fully expected that 
these disorders would be highly associated due to similar underlying pathophysiology and risk 
factors. Medications used to treat nerve disorder have side effects of weight gain (pregabalin & 
gabapentin), which might indirectly be causal in the development of insulin tolerance in type 2 
diabetes38, 39. However, because these medications also may be prescribed to treat diabetic 
neuropathy, this relationship was unclear. Similarly, the importance of common complications 
of type 2 diabetes reflects the current state of care, where patients should be assessed for type 2 
diabetes if they experience complications associated with the disease, such as decreased innate 
or acute immune function or neural pain. Overall, this list of positively associated factors for 
current type 2 diabetes was in consensus with the literature. Therefore, our results suggest that 
EHR research can determine effectively that each of these established risk factors were 
independent, and meaningful in the full context of the patient. 
 
The factors that decrease the likelihood of diabetes have been discussed less frequently in the 
literature, potentially because the cost of missing high-risk patients is greater than the benefit of 
identifying low-risk patients. Although there is no ICD-9 code for physical activity, the factors in 
this category reflect the treatment for mild discomfort, temporary pain, and potential athletic 
injuries. Athletic activity decreases insulin sensitivity, even when no weight loss is achieved, and 
this is important for the prevention and management of type 2 diabetes5. In contrast to these 
factors, we found also that markers of physical frailty, and diseases that inhibit food intake, 
decreased the risk of current type 2 diabetes. Patients with these conditions are at risk for 
muscle loss, which was associated negatively with type 2 diabetes40-42. In aggregate, these factors 
of increased activity or frailty can be viewed, alternatively, as signs of increased health 
consciousness. We found that patients who were integrated into the medical system or aware of 
the consequences of chronic disease were less likely to have current type 2 diabetes. 
 
One of the benefits of EHR research is that, in addition to verifying the factors that had a 
relatively clear interpretation, EHR mining can identify factors where the link with disease is 
either unproven or unsuspected. Some factors identified here are less established in the type 2 
diabetes literature. In particular, although some work has addressed the association of 
homosexuality, sexual identity disorders, and sexual deviancy (ICD-9 302.X) with diabetes43, 44, 
our results suggest that more work should be done to understand the link between diabetes and 
these factors, so that at-risk patients can be identified better. In contrast to increasing the risk of 
current type 2 diabetes, we are uncertain why allergic rhinitis (ICD-9 477.X), and use of depot 
medroxyprogesterone contraceptives, decreased the prevalence of type 2 diabetes. Even though 
type 2 diabetes has been shown to affect innate or acute immunity45, we are unaware of a strong 
link between type 2 diabetes and allergies, which primarily are a dysfunction of the adaptive or 
acquired immune system. Due to the underlying etiology behind the previous controversial link 
between exogenous hormone treatment for menopause and cardiovascular risk, we expect that 
the usage of depot medroxyprogesterone contraceptives reflects a patient population that 
engages in other activities that decrease type 2 diabetes risk, and not that depot 
medroxyprogesterone itself is protective for type 2 diabetes. The interpretation of each of these 
factors is unclear, therefore our results suggest that more work should be done to understand 
these observed links. 
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In addition to these interpretable factors, there were a number of factors that were associated 
negatively with type 2 diabetes, even though the literature suggested that the association should 
be positive. An established side effect of prednisone treatment is increased insulin resistance 
and steroid-induced type 2 diabetes46. Therefore, clinicians may prescribe prednisones only in 
low-risk patients. As noted above, type 2 diabetes is associated positively with disorders of the 
innate or acute immune system, metabolic syndrome and cardiac dysfunction; therefore we are 
uncertain why some of these factors were negatively associated with type 2 diabetes. Further, 
type 2 diabetes is a risk factor for hemorrhoids (ICD-9 455.X). Migraine also shares common 
comorbidities with type 2 diabetes47, including some we identified here. Therefore, we are 
uncertain why the diagnosis of migraine decreased the risk of current type 2 diabetes. Our EHR 
model found also that being a current smoker decreased the risk of diabetes, which reflects how 
smoking increases base metabolic rate. Yet, this contradicts at least one study in the literature48 
which found smoking increased diabetes risk. However, this difference may be due to how we 
controlled for many other factors, while previous studies on smoking and diabetes accounted for 
a limited number of confounders (e.g. age & BMI). These factors warrant further study to 
understand why our analysis of EHR records did not replicate previous work. 
 
While these results seem to summarize and review the major themes in research, we also 
identified factors that were not significantly associated, positively or negatively, with type 2 
diabetes, and are related to the themes we discussed above. This lack of significance could reflect 
either a lack of statistical power due to infrequent prescribing and thereby false negatives, or a 
lack of an effect. Not all disorders of acute or innate immunity or the treatment for those 
conditions were associated with type 2 diabetes. Even though some were, not all medications for 
hypertension and hypothyroidism or markers of physical frailty were associated with current 
type 2 diabetes. Medications hypothesized to be associated with diabetes, such as varenicline49, 
were not associated in our analysis.  
 
Our model also faced challenges with missing data such as family history, and did not contain 
several important risk factors for diabetes, such as ethnicity and socioeconomic status26, due to 
incomplete patient records. The missing data affected mainly the full EHR model, as the basic 
covariates (age, BMI, etc.) were rarely missing. Missing data in this population wasn’t addressed, 
but it could have been imputed to improve accuracy and reduce bias. Patients with Type 1 
diabetes were underrepresented in this sample.  Although we established a protocol for 
interpreting medication and laboratory test results, there was large variation in the reporting of 
these factors; therefore some bias and/or misreporting could be present. Due to privacy 
concerns, our model was unable to incorporate longitudinal information in the EHR that we 
would expect to improve its overall accuracy.  Moreover, this model was trained using patients 
who had a current diagnosis of Type 2 diabetes, which implicitly assumes that diagnosed and 
undiagnosed diabetes patients are similar, but this hypothesis needs to be confirmed.  In the 
future, we will confirm the profiles of diagnoses and undiagnosed patients using longitudinal 
data on an independent database, with a 12-18 month pre-index period with no diagnoses for 
Type I or II. 
 
It also was intriguing that a family history of diabetes did not show a strong effect. Along with 
poor family medical history reporting, this implies that even although there is a genetic link for 
type 2 diabetes, non-genetic factors may have more effectively identified at-risk patients.  We 
were not able to incorporate ethnicity information into this model, because such information 
was unavailable. Given that the prevalence of diabetes in the sample population (18.1%) greatly 
exceeded the general US diabetes prevalence (11.8%), this suggests that the sample population 
may have had an over-representation of minority patients.  The superior performance of the 
EHR phenotype model compared to the conventional model may indicate then that additional 
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health information provides additional diabetes risk factors that are especially relevant to 
minority populations.   
 
Conclusion 
 
Given that nearly 1 in 3 Americans will develop diabetes at some point in their lifetime, 
predicting and assessing diabetes risk on a population-wide scale is critical for both prevention 
and effective treatment. We anticipate that the largest adopter of EHR phenotype models will be 
insurers; risk scores will be created using existing claims databases. Given that the average 
patient with diabetes incurs over twice the expected cost as a patient without 7, there exists a 
significant financial incentive for insurers to reduce diabetes risk in patients they cover.   An 
EHR phenotype-based pre-screen could be used for national diabetes screening at little cost, as 
risk scores could be computed automatically within EHRs to efficiently identify patients who 
should undergo more formal and sensitive laboratory screening and/or preventive behavioral 
interventions.  Individual patients who are at high-risk for chronic and costly diseases will be 
targeted for patient-education programs, and reduction in calculated risk will be rewarded 
monetarily.    
 
These promising results showed EHR phenotypes provided superior predictive accuracy for 
assessing diabetes status, compared to traditional non-laboratory information (p<0.001). We 
have demonstrated that this is possible even in the face of a diverse, at-risk patient population, 
with missing and incomplete patient records pooled across practice locations. This suggests that 
incorporating more medical history would increase the accuracy of existing diabetes risk scores 
in at-risk patient populations, for step-wise screening. The total increase in accuracy for full 
screening is partially dependent upon how much of the additional information provided by the 
EHR is correlated with the laboratory testing. Due to the retrospective and correlative nature of 
EHR research, we cannot resolve whether the EHR phenotype risk factors were a cause or effect 
of diabetes, but this may match clinical practice where 25% of people with type 2 diabetes are 
undiagnosed. 
  
Given that this analysis showed superior prediction of diabetes using only 3 years of incomplete 
and unsystematically recorded data, we anticipate that the true signal and potential of an ideal, 
complete, and systematically utilized EHR is much greater than we demonstrate here. As EHRs 
become more widely used, we hope that the size and quality of the records will increase by 
orders of magnitude. This demands that future databases should be constructed in such a way as 
to allow easy data mining; and thereby to encourage researchers to develop prospective risk 
models27, 50. Reducing the amount of missing data would only strengthen the ability of these 
models to detect type 2 diabetes. 
 
We, and others, have advocated that data mining EHRs could be used to address numerous 
clinical challenges51-53, such as identifying patients at risk for depression, suicide, strokes, and 
cardiovascular events. Risk scores, not limited just to diabetes, should be automatically 
computed and included in a general patient profile, providing physicians an instant assessment 
of potential health conditions. EHR phenotypes additionally could be used for assessment of 
treatment efficacy, when incorporated into statistical models such as a propensity score 28.   
 
Beyond prediction, using EHR-phenotype models provide invaluable information about the risk 
factors themselves. For example, EHRs can be used to assess comparative risks of medication 
classes (as is being done54), and answer important treatment questions, including whether 
statins or fibrates should be used to treat high cholesterol in patients with diabetes. However, 
our experience with hormonal therapy for menopause55 taught us that, while there is great 
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potential in retrospective, observational studies, the highest level of evidence is a double-
blinded, randomized clinical trial. Because of this, resulting associations with diabetes are 
necessarily ambiguous, with no defined causal relationship, and need to be carefully scrutinized 
in light of complementary controlled studies27.   For screening of a disease that is both the fifth 
leading cause of preventable death in the United States and has a tremendous rate of 
undiagnosed patients, we argue that the accuracy of the model is more important any causal 
inference of the predictors. Because the EHR and data mining are both nascent, there is a vast 
unexplored territory with applications so broad they have yet to be defined. 
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Figure 1:  ROC Curve comparing Traditional to EHR phenotype Diabetes 
Prediction, using logistic regression model. 
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Figure 2:  ROC Curve comparing Traditional to EHR phenotype Diabetes 
Prediction, using random forests holdout models. 
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